Oppenheimer Issues Positive Forecast for Opus Genetics (NASDAQ:IRD) Stock Price

Opus Genetics (NASDAQ:IRD) had its price target lifted by analysts at Oppenheimer from $10.00 to $20.00 in a note issued to investors on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s target price indicates a potential upside of 249.04% from the company’s current price.

Other equities research analysts have also recently issued research reports about the stock. Royal Bank Of Canada lowered their price target on shares of Opus Genetics from $10.00 to $9.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Citizens Jmp reissued a “market outperform” rating and issued a $11.00 target price on shares of Opus Genetics in a research report on Monday, June 15th. Leerink Partners started coverage on Opus Genetics in a research note on Thursday, May 21st. They issued an “outperform” rating and a $10.00 target price on the stock. Zacks Research raised Opus Genetics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 11th. Finally, BTIG Research reiterated a “buy” rating and set a $12.00 price target on shares of Opus Genetics in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Opus Genetics has an average rating of “Moderate Buy” and a consensus target price of $11.69.

Opus Genetics Price Performance

Shares of Opus Genetics stock traded up $1.39 during trading hours on Wednesday, hitting $5.73. 53,465,596 shares of the company’s stock traded hands, compared to its average volume of 1,276,095. The stock has a market capitalization of $473.58 million, a price-to-earnings ratio of -4.24 and a beta of 0.58. Opus Genetics has a 12-month low of $1.32 and a 12-month high of $7.07. The company has a fifty day simple moving average of $3.79 and a 200-day simple moving average of $4.29.

Opus Genetics (NASDAQ:IRD) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%. The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $2.63 million. On average, analysts forecast that Opus Genetics will post -0.99 EPS for the current fiscal year.

Insider Activity

In other Opus Genetics news, CFO Robert Gagnon sold 28,000 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $4.54, for a total value of $127,120.00. Following the completion of the transaction, the chief financial officer owned 556,375 shares in the company, valued at $2,525,942.50. This trade represents a 4.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO George Magrath sold 9,475 shares of Opus Genetics stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total value of $27,951.25. Following the transaction, the chief executive officer directly owned 1,731,869 shares of the company’s stock, valued at $5,109,013.55. The trade was a 0.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 57,331 shares of company stock valued at $213,749. 11.70% of the stock is owned by corporate insiders.

Institutional Trading of Opus Genetics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Comerica Bank bought a new position in shares of Opus Genetics in the first quarter worth $29,000. Royal Bank of Canada purchased a new position in shares of Opus Genetics during the first quarter worth about $299,000. Nantahala Capital Management LLC raised its stake in Opus Genetics by 6.0% in the second quarter. Nantahala Capital Management LLC now owns 3,345,923 shares of the company’s stock valued at $3,152,000 after purchasing an additional 188,028 shares in the last quarter. Mink Brook Asset Management LLC grew its stake in Opus Genetics by 47.8% in the 2nd quarter. Mink Brook Asset Management LLC now owns 1,197,616 shares of the company’s stock worth $1,128,000 after buying an additional 387,536 shares in the last quarter. Finally, Opaleye Management Inc. lifted its holdings in shares of Opus Genetics by 3.8% during the 2nd quarter. Opaleye Management Inc. now owns 1,220,000 shares of the company’s stock worth $1,149,000 after acquiring an additional 45,000 shares during the last quarter. Institutional investors own 14.97% of the company’s stock.

Trending Headlines about Opus Genetics

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Positive Phase 1/2 results: All five participants in the low-dose Cohort 1 of the BIRD-1 trial showed clinically meaningful improvement in visual function, while four participants demonstrated structural improvements. Three of five patients achieved meaningful best-corrected visual acuity gains, and three of four evaluable patients improved retinal sensitivity. No serious adverse events or dose-limiting toxicities were reported. Opus Genetics Announces Positive Low Dose Cohort 1 Data
• Positive Sentiment: Regulatory and development progress: Following a successful FDA Type C meeting, the agency aligned with a potential pivotal endpoint combining at least a three-decibel microperimetry improvement with patient-reported outcomes. Opus expects to complete Cohort 2 dosing in the fourth quarter of 2026, report initial data in the second quarter of 2027, and potentially begin Phase 3 dosing in 2027. The company also expects its cash runway to extend into 2029.
• Positive Sentiment: Analyst support strengthened: HC Wainwright reaffirmed a Buy rating with an $8 price target, while BTIG Research maintained Buy with a $12 target and Chardan Capital reiterated Buy with a $13 target. These targets imply substantial potential upside from recent trading levels and reinforce investor confidence in the program.
• Positive Sentiment: Speculative buying increased: Investors purchased 4,820 call options, roughly 681% above typical volume, signaling heightened bullish positioning. The stock also experienced exceptionally heavy trading activity as the clinical update attracted attention.
• Neutral Sentiment: Institutional interest: BlackRock, Trails Edge Capital Partners, Nantahala Capital Management and other funds recently established or increased positions. Institutional and hedge-fund ownership is approximately 15%, providing some additional sponsorship but not guaranteeing future performance.
• Negative Sentiment: Insider sale: CFO Robert Gagnon sold 28,000 shares for $127,120 to cover tax withholding tied to vested equity awards. The transaction reduced his holdings by 4.79%, although he continues to own more than 556,000 shares.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.